Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results

K. L. Reckamp; P. Gilman; B. Halmos; M. Jahanzeb; J. McCann; H. Paripati; L. C. Seneviratne; J. A. Wallace; B. Rueter; A. Esler; E. Dowling; M. Koczywas

doi:10.1093/annonc/mdy292.078

Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results

K. L. Reckamp, P. Gilman, B. Halmos, M. Jahanzeb, J. McCann, H. Paripati, L. C. Seneviratne, J. A. Wallace, B. Rueter, A. Esler, E. Dowling, M. Koczywas

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	viii527
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy292.078
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy292.078

Cite this

Reckamp, K. L., Gilman, P., Halmos, B., Jahanzeb, M., McCann, J., Paripati, H., Seneviratne, L. C., Wallace, J. A., Rueter, B., Esler, A., Dowling, E., & Koczywas, M. (2018). Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii527. https://doi.org/10.1093/annonc/mdy292.078

Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results. / Reckamp, K. L.; Gilman, P.; Halmos, B. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii527.

Research output: Contribution to journal › Article › peer-review

Reckamp, KL, Gilman, P, Halmos, B, Jahanzeb, M, McCann, J, Paripati, H, Seneviratne, LC, Wallace, JA, Rueter, B, Esler, A, Dowling, E & Koczywas, M 2018, 'Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii527. https://doi.org/10.1093/annonc/mdy292.078

Reckamp KL, Gilman P, Halmos B, Jahanzeb M, McCann J, Paripati H et al. Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii527. doi: 10.1093/annonc/mdy292.078

@article{21805e05e1ea4f3c9037524acd2de02b,

title = "Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results",

author = "Reckamp, {K. L.} and P. Gilman and B. Halmos and M. Jahanzeb and J. McCann and H. Paripati and Seneviratne, {L. C.} and Wallace, {J. A.} and B. Rueter and A. Esler and E. Dowling and M. Koczywas",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy292.078",

language = "English (US)",

volume = "29",

pages = "viii527",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations

T2 - Preliminary results

AU - Reckamp, K. L.

AU - Gilman, P.

AU - Halmos, B.

AU - Jahanzeb, M.

AU - McCann, J.

AU - Paripati, H.

AU - Seneviratne, L. C.

AU - Wallace, J. A.

AU - Rueter, B.

AU - Esler, A.

AU - Dowling, E.

AU - Koczywas, M.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081529611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081529611&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy292.078

DO - 10.1093/annonc/mdy292.078

M3 - Article

C2 - 32137367

SN - 0923-7534

VL - 29

SP - viii527

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this